MDT - Medtronic plc

NYSE - NYSE Delayed price. Currency in USD
107.58
+0.16 (+0.15%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous close107.42
Open108.52
Bid107.21 x 900
Ask108.32 x 800
Day's range107.44 - 108.74
52-week range81.66 - 112.05
Volume3,658,460
Avg. volume4,472,046
Market cap144.337B
Beta (3Y monthly)0.49
PE ratio (TTM)32.99
EPS (TTM)3.26
Earnings date19 Nov 2019
Forward dividend & yield2.16 (2.01%)
Ex-dividend date2019-09-26
1y target est117.65
Trade prices are not sourced from all markets
  • Medtronic (MDT) Gains But Lags Market: What You Should Know
    Zacks

    Medtronic (MDT) Gains But Lags Market: What You Should Know

    Medtronic (MDT) closed at $107.42 in the latest trading session, marking a +0.63% move from the prior day.

  • Here's Why You Should Add Stryker (SYK) to Your Portfolio Now
    Zacks

    Here's Why You Should Add Stryker (SYK) to Your Portfolio Now

    Stryker's (SYK) core Mako Platform has been consistently driving its top line.

  • 4 Stocks From Highest Job-Creating Sectors in September
    Zacks

    4 Stocks From Highest Job-Creating Sectors in September

    Apart from the decent number of new jobs, the unemployment rate in the United States dropped 0.2 percentage points to hit a five-decade low of 3.5% last month.

  • Medtronic Submits Two Pelvic Health Devices for FDA's PMA
    Zacks

    Medtronic Submits Two Pelvic Health Devices for FDA's PMA

    Medtronic's (MDT) filing for both its InterStim products to gain FDA's PMA is its essential bid to boost its Pelvic Health & Gastric Therapies business.

  • Stratasys Unveils Medical 3D Printer, Boosts Market Foothold
    Zacks

    Stratasys Unveils Medical 3D Printer, Boosts Market Foothold

    Stratasys' (SSYS) new 3D printer is especially beneficial for medical device companies, which require new ways to drive faster adoption of technologies and procedures.

  • Medtronic Gets FDA's Breakthrough Device Nod for Valiant TAAA
    Zacks

    Medtronic Gets FDA's Breakthrough Device Nod for Valiant TAAA

    This FDA designation is expected to bolster Medtronic's (MDT) Aortic, Peripheral & Venous line within the broader Cardiac and Vascular group.

  • Here's Why You Should Hold on to Teleflex (TFX) Stock Now
    Zacks

    Here's Why You Should Hold on to Teleflex (TFX) Stock Now

    Investor confidence is still high on Teleflex (TFX), thanks to solid prospects.

  • Axonics (AXNX) Upbeat on Results of Its ARTISAN-SNM Study
    Zacks

    Axonics (AXNX) Upbeat on Results of Its ARTISAN-SNM Study

    Axonics (AXNX) expects to improve performance on the positive outcome of the study.

  • Did Medtronic plc's (NYSE:MDT) Recent Earnings Growth Beat The Trend?
    Simply Wall St.

    Did Medtronic plc's (NYSE:MDT) Recent Earnings Growth Beat The Trend?

    When Medtronic plc's (NYSE:MDT) announced its latest earnings (26 July 2019), I wanted to understand how these figures...

  • Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Medtronic (MDT) closed at $106.93, marking a +0.93% move from the previous day.

  • Tandem Diabetes' Inland Sales and Product Suite Are Tailwinds
    Zacks

    Tandem Diabetes' Inland Sales and Product Suite Are Tailwinds

    Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).

  • Abiomed's (ABMD) Impella 5.5 With SmartAssist Gets FDA Nod
    Zacks

    Abiomed's (ABMD) Impella 5.5 With SmartAssist Gets FDA Nod

    Abiomed's (ABMD) flagship Impella heart pump line is a major growth driver.

  • Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT
    Zacks

    Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT

    Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.

  • Investors Binge on Record $308 Billion of Company Bond Sales
    Bloomberg

    Investors Binge on Record $308 Billion of Company Bond Sales

    (Bloomberg) -- Companies globally sold a record amount of bonds in September as investors hungry for yield poured into debt, betting that major central banks can keep the global economy out of a recession and the worst can be avoided in the U.S.-China trade war.Firms from Apple Inc. to France’s Orange and Japan’s SoftBank Group Corp. sold more than $308 billion of notes, the first time ever that corporate issuance has topped the $300 billion mark in a month, according to data compiled by Bloomberg. Sales globally this year are on track to exceed the equivalent of $2 trillion at the fastest pace ever.The onslaught of investment-grade deals in the U.S. may ease to about $200 billion in the last quarter as tight spreads potentially make investors more cautious and they position for 2020, JPMorgan Chase & Co. said. Pacific Investment Management Co. said last month that it is “cautious” on corporate credit, and favors short-dated names and those that are less likely to default.“To the extent that new issuance is credit enhancing -- refinancing and or extending the maturities of its debt -- then the issuance is good for the companies as well the current bondholders,” said Todd Schubert, head of fixed-income research at Bank of Singapore Ltd. “Many of the issues that I have seen fall under this category.”‘Massive Snowball’ Effect to Spur China Bond Defaults AbroadEuropean surgeIn Europe, corporate bond sales have already set a full-year record with three months still left to go. Year-to-date investment-grade euro corporate bond issuance reached 582 billion euros ($636 billion) Tuesday, beating full-year totals dating back to at least 2014, Bloomberg data show. The tally includes 94.5 billion euros of September deals, well above a previous 90.3 billion euros record set in January.U.S. borrowers such as Medtronic Plc and Thermo Fisher Scientific Inc. have sold a market-leading 68 billion euros of bonds this year, partly to refinance costlier dollar debt. That tally is set to go even higher, with computer maker Dell Technologies Inc meeting investors from today for a planned debut sale of euro bonds, according to a person with knowledge of the matter, who declined to be identified citing company policy.“Fifty billion euros-plus is easily achievable in the final quarter, even if the markets generally start to wobble in the face of macro and/or geopolitical event risk,“ said Suki Mann, founder of Creditmarketdaily.com, in a note to clients. He believes treasury desks are likely to “opportunistically pre-fund obligations which might not be maturing for another twelve months.”U.S. RecordsSeptember’s new U.S. investment-grade debt supply reached $158 billion, making it the third-largest month ever for issuance. It was a month for the record books: an unprecedented 130 issuers tapped debt capital markets after a frenzied start that made the first week the busiest market participants had seen in their careers.The market’s ability to digest the supply boom was just as notable as the sheer volume of borrowers that came to market. Global demand for higher-yielding U.S. corporate debt underpinned sales, and investment-grade spreads closed about 5 basis points tighter over the course of September, finishing at 115 basis points over Treasuries Monday.Risks have caught up with more borrowers recently, though. Corporate defaults in 2019 worldwide already match those in 2018, with 82 globally this year, S&P Global Ratings said on Sept. 26.Still, with the global economy seen growing at or just below 3%, a lack of clear direction in U.S. interest rates, and a possible pause in U.S.-China trade tensions, Goldman Sachs Group Inc. expects the search for yield among investors to continue. Those factors are supportive of the bank’s preference for high-yield bonds over investment grade in Asia, it said in a report Friday.(Updates with U.S. September supply details from eighth paragraph)\--With assistance from Brian Smith, Claire Boston and Michael Gambale.To contact the reporters on this story: Finbarr Flynn in Tokyo at fflynn3@bloomberg.net;Hannah Benjamin in London at hbenjamin1@bloomberg.netTo contact the editors responsible for this story: Andrew Monahan at amonahan@bloomberg.net, ;Vivianne Rodrigues at vrodrigues3@bloomberg.net, Beth ThomasFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Here's Why You Should Hold on to Quest Diagnostics Stock Now
    Zacks

    Here's Why You Should Hold on to Quest Diagnostics Stock Now

    Investor confidence is high on Quest Diagnostics (DGX) stock, thanks to solid prospects.

  • Illumina, Broad Institute Partner on Secondary Genomic Analysis
    Zacks

    Illumina, Broad Institute Partner on Secondary Genomic Analysis

    The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.

  • Medtronic (MDT) Gets FDA Nod to Study Intrepid TMVR System
    Zacks

    Medtronic (MDT) Gets FDA Nod to Study Intrepid TMVR System

    The FDA clearance is expected to boost Medtronic's (MDT) structural heart business.

  • Medtronic's All Business Lines Grow Despite Cost Concerns
    Zacks

    Medtronic's All Business Lines Grow Despite Cost Concerns

    Within Diabetes group, Medtronic (MDT) is seeing a strong adoption of the Guardian Connect Smart CGM system.

  • Has Medtronic (MDT) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Medtronic (MDT) Outpaced Other Medical Stocks This Year?

    Is (MDT) Outperforming Other Medical Stocks This Year?

  • Top Stock Reports for Apple, Comcast & Nike
    Zacks

    Top Stock Reports for Apple, Comcast & Nike

    Top Stock Reports for Apple, Comcast & Nike

  • The Zacks Analyst Blog Highlights: Varian, Stryker and Medtronic
    Zacks

    The Zacks Analyst Blog Highlights: Varian, Stryker and Medtronic

    The Zacks Analyst Blog Highlights: Varian, Stryker and Medtronic

  • Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now
    Zacks

    Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now

    Investor confidence continues to be high in Zimmer Biomet (ZBH), thanks to solid prospects.

  • 3 MedTech Stocks in Focus on Emerging Market Prospects
    Zacks

    3 MedTech Stocks in Focus on Emerging Market Prospects

    Emerging market countries present lucrative prospects; consequently, investors can take a look at the space.

  • FDA Nods to Medtronic's (MDT) New Age Evolut PRO+ TAVR
    Zacks

    FDA Nods to Medtronic's (MDT) New Age Evolut PRO+ TAVR

    This latest FDA approval of Medtronic's (MDT) Evolut PRO+ follows the last month's nod from the regulatory body for the Evolut TAVR system with regard to expanded indication.

  • Medtronic's MiniMed 670G Shows Favorable Outcome in Europe
    Zacks

    Medtronic's MiniMed 670G Shows Favorable Outcome in Europe

    Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more